Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer
1 other identifier
interventional
47
1 country
1
Brief Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2005
CompletedFirst Submitted
Initial submission to the registry
October 11, 2011
CompletedFirst Posted
Study publicly available on registry
October 13, 2011
CompletedOctober 13, 2011
October 1, 2011
October 11, 2011
October 12, 2011
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- histologically proved breast cancer with metastatic disease
You may not qualify if:
- life expectancy less than 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- TTY Biopharmlead
Study Sites (1)
CGMH
Linko, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hsien-Kun Chang
Chang Gung Memorial Hospital, Lin-Kou Medical Center
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 11, 2011
First Posted
October 13, 2011
Study Start
September 1, 2005
Last Updated
October 13, 2011
Record last verified: 2011-10